Novo Nordisk

622.6

DKK

+5.67 %

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

214 following

+5.67%

-17.09%

-25.2%

-36.98%

-10.82%

-10.43%

+72.78%

+218.26%

+49,908.03%

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Market cap

2.78T DKK

Turnover

5.4B DKK

Revenue

232.26B

EBIT %

44.16 %

P/E

33.35

Dividend yield-%

1.51 %

Financial calendar

5.2

2025

Annual report '24

7.5

2025

Interim report Q1'25

6.8

2025

Interim report Q2'25

ShowingAll content types

Aktier i Vælten - Novo Nordisk: Vi må vente på re-eksamen efter skuffende data

Video12/20/2024, 2:26 PM

Aktier i Vælten - Novo Nordisk: Vi må vente på re-eksamen efter skuffende data

Novo Nordisk er her fredag ude med Cagrisema data, der skuffer med vægttab på 22,7% vs. forventet 25%. Nyheden trækker aktien markant ned med omkring -20% i skrivende stund. Vi har set nærmere på nyheden, og om faldet er berettiget samt givet perspektiver på, hvilken prissætning (forward P/E) aktien historisk har handlet til.

Regulatory press release12/20/2024, 12:47 PM

Novo Nordisk A/S - share repurchase programme

Regulatory press release12/20/2024, 10:41 AM

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/18/2024, 1:59 PM

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

Regulatory press release12/16/2024, 12:51 PM

Novo Nordisk A/S - share repurchase programme

Press release12/16/2024, 6:29 AM

Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

Regulatory press release12/14/2024, 5:08 AM

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Regulatory press release12/12/2024, 1:47 PM

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events

Regulatory press release12/9/2024, 3:43 PM

Novo Nordisk A/S - share repurchase programme

Regulatory press release12/6/2024, 6:10 PM

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Regulatory press release12/2/2024, 11:45 AM

Novo Nordisk A/S - share repurchase programme

Regulatory press release11/25/2024, 3:16 PM

Novo Nordisk A/S - share repurchase programme

Regulatory press release11/19/2024, 1:33 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Regulatory press release11/18/2024, 3:08 PM

Novo Nordisk A/S - share repurchase programme

Regulatory press release11/13/2024, 4:18 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Regulatory press release11/12/2024, 7:00 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Regulatory press release11/8/2024, 9:21 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Regulatory press release11/8/2024, 8:51 PM

Novo Nordisk A/S - share repurchase programme

Regulatory press release11/8/2024, 8:47 PM

Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme

Regulatory press release11/8/2024, 2:07 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.